 |
|
The Irony of Autism
Arch Gen Psychiatry. 1998;55:643-644.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
IN THIS issue of the ARCHIVES, McDougle and colleagues1 report on another interesting, placebo-controlled trial of psychotropic medication in the treatment of autism. Following their study of fluvoxamine,2 McDougle and colleagues demonstrate the efficacy for risperidone in the treatment of severe behavioral problems frequently, but not invariably, found in persons with autistic disorder. These are important and valuable findings. So, with all this good news, what is the irony?
Since Kanner3 first named the disorder in 1943, there have been enormous advances in the study of autism. Among the most important has been the precise and internationally agreed on definition of the syndrome of autism. Yet ironically, the subjects in this study are imprecisely defined and the ascertainment of this clinical population is not well articulated. There is also a lack of clarity about the diagnoses, and thus it is unclear whether this population represents a minority of adults with . . . [Full Text of this Article]
RELATED ARTICLE
A Double-blind, Placebo-Controlled Study of Risperidone in Adults With Autistic Disorder and Other Pervasive Developmental Disorders
Christopher J. McDougle, Janice P. Holmes, Derek C. Carlson, Gregory H. Pelton, Donald J. Cohen, and Lawrence H. Price
Arch Gen Psychiatry. 1998;55(7):633-641.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Risperidone Reduces Behavioral Symptoms of Autism in Adults
JWatch Psychiatry 1998;1998:8-8.
FULL TEXT
|
